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A single layer of intestinal epithelial cells (IEC) lines the entire gastro-
intestinal tract and provides the first line of defense and barrier against an
abundance of microbial stimuli. IEC homeostasis and repair are mediated
through microbe-sensing Toll-like receptor (TLR)-induced inflammatory
pathways. Increasing evidence supports a role of suppressor of cytokine
signaling 3 (SOCS3) as a modulator of IEC turnover, balancing con-
trolled repair and replenishment with excessive IEC proliferation predis-
posing to dysplasia and cancer. Our data indicate that SOCS3 can limit
microbial-induced IEC repair, potentially through promoting tumor ne-
crosis factor- (TNF-) and limiting TNFR2 expression. Activation of
TLR5 signaling pathways, compared with other TLR, increases TNF-
mRNA in a dose-dependent manner and SOCS3 enhances TLR5-induced
TNF-. We also show that flagellin promotes transcription of TNFR2
and that SOCS3 limits this expression, presenting a mechanism of
SOCS3 action. Our data also support the role of microbial ligands in
epithelial wound healing and suggest that a functional consequence of
increased TNF- is reduced wound healing. These results provide further
evidence to support the regulatory role of epithelial SOCS3 in intestinal
health and suggest that the increased expression of SOCS3 observed in
IBD may serve to perpetuate “inflammation” by promoting TNF-
production and limiting epithelial repair in response to commensal mi-
croflora.
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THE HOMEOSTATIC INFLUENCE of microbiota on intestinal epithe-
lial cell (IEC) turnover occurs in an actively regulated envi-
ronment, dictated by signals between the microbiota, IEC, and
IEC-conditioned components of the immune system (2, 23).
IEC are able to converse with microbes in the colon via a
cohort of pattern recognition receptors including Toll-like
receptors (TLR) (1). TLR signaling is paramount in driving
intestinal tissue repair and regeneration (19), as evidenced by
germ-free mice and mice deficient in MyD88 having an im-
paired ability to repair intestinal injury (20). TLR-2, TLR-4,
and TLR-5 knockout mice, though not to the same extent as
MyD88/ mice, have a reduced capacity to repair colonic
mucosa and reduced barrier function, with TLR5 knockout
mice developing spontaneous colitis (20, 27). TLR signaling
pathways are important activators of NF-B, driving the ex-
pression of a number of “proinflammatory” genes such as
TNF-, IL-6, and IL-8 essential for tissue repair and mainte-
nance of barrier function (26). However, persistent activation
of such pathways can lead to certain pathologies, including
chronic inflammation characteristic of inflammatory bowel
disease (IBD) and some cancers. Failure to regulate microbial
interactions is implicated in the onset of IBD, where damage to
the intestinal barrier is characteristic of chronic relapse and
remittance of inflammation.
Suppressor of cytokine signaling-3 (SOCS3), an endogenous
modulator of IEC turnover, is upregulated in IBD (15, 24).
SOCS3 is a tumor suppressor in the intestine (21), as IEC-
targeted deletion of SOCS3 promotes tumor burden in the
colon, with methylated silencing of SOCS3 shared in multiple
tumor types (12, 17, 21). SOCS3 is also a potent suppressor of
proliferation in both transformed and nontransformed IEC
lines, supporting a role in mediating IEC turnover, ostensibly
due to regulation of “inflammatory” signaling, for example by
limiting TNF--induced NF-B translocation and IL-6-in-
duced STAT3 phosphorylation (9, 12, 17, 21).
It has been well documented that levels of TNF- are
elevated in serum and intestinal mucosa of patients with IBD
with neutralization of TNF-, the basis of anti-TNF therapy,
being associated with improved health, particularly in patients
with Crohn’s disease (25). TNF- signals through a family of
receptors, including two transmembrane receptors, TNFR1 and
TNFR2. TNF- signaling through TNFR1 and TNFR2 induces
the activation of the transcription factors AP-1 and NF-B, linked
to cell proliferation, survival, and/or apoptosis (3). TNFR2 is
upregulated in IBD and in models of inflammation-associated
cancer (6, 16, 18), regarded to be in response to increased
inflammatory cytokines in the mucosa, as TNF- and IL-6 induce
TNFR2 in colon cancer cells (9, 16). TNF- is shown to be a
major mediator of epithelial barrier dysfunction (7, 28, 29), and
TNF--induced loss of intestinal epithelial barrier function re-
quires both TNFR1 and TNFR2 signaling (8).
We propose that SOCS3, ostensibly an endogenous inhibitor
of inflammatory signaling and proliferation, paradoxically pro-
motes intestinal inflammation, possibly through limiting mi-
crobial-induced TNFR2 expression, enhancing TNF- produc-
tion and thus limiting epithelial barrier repair.
MATERIALS AND METHODS
Cell lines and culture. SW480 (ECACC), human colorectal cancer
IEC, were maintained in Leibovitz growth medium (GIBCO) supple-
mented with 10% fetal bovine serum (FBS), 50 units/ml of penicillin
and streptomycin (Sigma), and 0.1 mg/ml sodium pyruvate. Caco-2
epithelial cell line (ECACC), was maintained in MEM (GIBCO)
supplemented with 10% FBS, 50 units/ml of penicillin and strepto-
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mycin, and 1% MEM Non-Essential Amino Acids (GIBCO). Cells
were allowed to differentiate under an atmosphere of 95% (vol/vol)
air-5% CO2 at 37°C in a humidified incubator.
Generation of SOCS3-overexpressing cells. The mammalian ex-
pression vector pIRESneo, with and without the full-length human
SOCS3 cDNA and containing the Gentacin antibiotic resistance
cassette, was purchased from Epoch Life Science. Plasmids were
linearized with Ahd1 (NEB no. R0584S) prior to ethanol precipita-
tion. For transfection, cells were seeded at a concentration of 1 
106/ml and incubated with Lipofectamine 2000 (Invitrogen) and
plasmid DNA, with and without the full-length human coding SOCS3
cDNA, referred to as SOCS3hi and SOCS3norm, respectively, accord-
ing to manufacturer’s instructions. G418 antibiotic, at varying con-
centrations, was used to select transfected IEC. Medium containing
0.4 mg/ml G418 antibiotic was used to maintain transfected IEC
during culture. To validate overexpression of SOCS3, protein and
mRNA levels were measured in SOCS3norm and SOCS3hi IEC.
SOCS3hi depicted a 12 2-fold increase in SOCS3 mRNA compared
with SOCS3norm IEC. Immunoblotting showed a 1.3  0.1-fold
increase in SOCS3 protein expression compared with SOCS3norm IEC
(data not shown).
Stimulation with TLR ligands. SOCS3norm and SOCS3hi IEC at a
concentration of 2  105/ml were allowed to adhere for 3 days, with
serum deprivation overnight before treatment. IEC were treated with
polyinosinic:polycytidylic acid [Poly(I:C)] (InvivoGen), LPS Esche-
richia coli (Sigma), flagellin Salmonella typhimurium (InvivoGen) or
Trichuris muris excretory/secretory protein (ES, gift from K. Else) at
varying concentrations and times. Supernatant was collected and
stored at 80°C for ELISA assays and IEC lysed with either TRI
Reagent (for RNA, Sigma) or lysis buffer (Western blot) or fixed for
immunohistochemistry.
qRT-PCR. Total RNA from each sample was extracted by using
TRI Reagent according to the manufacturer’s instructions. The con-
centration and purity of RNA was determined by use of the NanoDrop
2000c (Thermo Scientific). Reverse transcriptase (RT) was performed
by using the Enhanced Avian RT First Strand Synthesis Kit (Sigma)
with Anchored oligo(dT) (Thermo Scientific) and PCR nucleotide mix
(Fisher) to generate cDNA by using 2 g of RNA. TNF- validated
primers were purchased from Primerdesign, reconstituted, and used as
specified in the supplemental data sheet. The TNFR2, SOCS3, and
housekeeping gene RPLPO primers were designed and checked for
specificity by use of BLAST search from the National Center for
Biotechnology Information (NCBI). Forward and reverse primers
(Sigma) were first reconstituted in autoclaved Milli-Q water to 100
M according to the supplied data sheet before being used to amplify
TNFR2, SOCS3, and RPLPO cDNA. The primer sequences used to
amplify TNFR2 (148 bp) were Forward: GAGTGGTGAACTGTGT-
CATGA and Reverse: GAGCTCGGCGCTGTGATC; SOCS3 (119
bp) Forward: TCGATTCGGGACCAGCCCCC and Reverse: TGCT-
GTGGGTGACCATGGCG; and RPLPO (142 bp) Forward: GCAAT-
GTTGCCAGTGTCTG and Reverse: GCCTTGACCTTTTCAGCAA.
qRT-PCR analysis. Real-time PCR was performed by using the
SYBR Green JumpStart Taq ReadyMix (Sigma) and the C1000
Real-Time Thermocycler (Bio-Rad). Cycling conditions were 94°C
for 2 min, 40  94°C for 15 s, and 60°C for 1 min. Gene expression
was calculated using the R  2(		Ct) method, where changes in Ct
values for the gene of interest were normalized relative to the
“housekeeping gene” RPLPO. In all experiments, gene expression
was expressed as fold change relative to no-treatment control. Real-
time PCR reactions were carried out in duplicate and replicated in a
minimum of three independent experiments.
Western blot. Cells were lysed in 100 l of lysis buffer (150 nM
NaCl, 50 mM Tris·HCl, 2 mM EDTA, 1 mM NaVO4, 1 mM NaF, and
1% Nonidet P-40) supplemented with protease and phosphatase in-
hibitor cocktails. Samples were spun at 4°C at 12,000 rpm for 10 min,
and Bradford reagent (Sigma) was used to determine protein concen-
tration. We boiled 25 g of protein with 4 sample buffer (Invitro-
gen) and 2-mercaptoethanol (Sigma) at 95°C for 10 min and per-
formed SDS-PAGE. Proteins were transferred onto nitrocellulose
membrane (Macherey-Nagel) by using the Trans-Blot Turbo Transfer
system (Bio-Rad). Membranes were blocked with 3% BSA in TBS for









































Fig. 1. Fold increase in tumor necrosis factor-
(TNF-; A and B) and suppressor of cytokine
signaling 3 (SOCS3; C) mRNA following 2 h
stimulation with microbial products relative to
no treatment. A: polyinosinic:polycytidylic acid
[Poly(I:C); P(I:C); 0.1 g/ml], LPS (0.1 g/ml),
flagellin (FLA; 0.1 g/ml), and Trichuris muris
excretory/secretory protein (ES; 0.1 mg/ml) were
added to the culture medium. Flagellin was the
only Toll-like receptor (TLR) ligand shown to
significantly promote TNF- mRNA (n  5). B:
flagellin promoted TNF- expression in a dose-
dependent manner (n  5). C: flagellin did not
induce SOCS3 mRNA relative to no-treatment





















Fig. 2. SOCS3 overexpression enhanced flagellin-induced TNF- mRNA in a
dose-dependent manner. Bar chart depicts fold increase in TNF- mRNA, in
Control (SOCS3norm) and SOCS3 overexpressing (SOCS3hi) intestinal
epithelial cells (IEC) relative to no-treatment (No Tx) SOCS3norm, follow-
ing 2-h flagellin treatment. *P  0.05 vs. No Tx; **P  0.05 SOCS3norm
vs. SOCS3hi.
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STAT3 (Santa Cruz no. sc-8019), p65 (Cell Signaling no. 3037S),

-actin (Cell Signaling no. 4967), and horseradish peroxidase-conju-
gated secondary antibody (Santa Cruz nos. sc-2030 and sc-2031) were
used and their presence was quantified by use of the ChemiDoc XRS
imaging system (Bio-Rad). The densitometry signal from loading
control 
-actin was used to normalize signal from p65 and pSTAT3
bands.
Immunocytochemistry. IEC were seeded onto coverslips at 1  105
IEC/well and allowed to adhere overnight. Following flagellin treat-
ment, medium was removed and coverslips were washed three times
in PBS. IEC were fixed in ethanol:methanol for 10 min at 20°C,
blocked in 2% BSA for 30 min at room temperature, and incubated in
0.5 g/ml of Anti-Human sTNF Receptor Type II (Peprotech 500-
P168) at 4°C overnight. Secondary antibody Alexa Fluor 488 donkey
anti-rabbit IgG (Life Technologies, 1:200) was used and cells were
counterstained with propidium iodide (Life Technologies, P3566)
1:3,000 in PBS for 1 min, coverslipped, and mounted onto slides to be
viewed via the Zeiss LSM 510 Meta Confocal Microscope.
Wound healing assay. Wound healing assay was performed by a
modified method as described by Han and colleagues (11). Caco-2
cells (2  105 cells/well) were seeded at 80–90% confluence in a
24-well plate and allowed to form monolayers for 7 days at 37°C.
After 7 days, linear wounds were made with a sterile 10-l plastic
pipette tip. Wells were washed three times in PBS to remove displaced
cells and treated as required. Images of wounds were obtained using
the confocal microscope (Leica DMIRE2 inverted microscope) at
10  magnification by using standard protocols at the predetermined
location at 0 h and 48 h after wounding. The total area of the wound
was measured with ImageJ and data were calculated as % wound
healed vs. 0 h. Medium and respective treatments were replaced after
24 h to remove dislodged cells, replenish nutrients, and restore
treatment levels.
Statistical analysis. Experiments were repeated multiple times and
data were pooled together. To determine statistical significance,
ANOVA was performed with two-sided Dunnett’s or Tukey’s post
hoc tests where appropriate.
RESULTS
TLR5 ligation promotes TNF- in a dose-dependent
manner. To determine the effect of TLR ligation on IEC
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Fig. 3. Flagellin treatment did not promote
STAT3 phosphorylation or NF-B p65 activa-
tion relative to No Tx. A: representative West-
ern blot of pSTAT3 and p65 following 2-h
flagellin or LPS stimulation at varying concen-
trations. B: average relative pSTAT3 and p65
(n  3) expression following 2-h stimulation.
SOCS3 limited LPS (10 mg/ml)-induced p65
*P  0.05 vs. No Tx. norm, Normal; hi, high.
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nists: Poly(I:C) (TLR3), flagellin (TLR5), LPS (TLR4), or T.
muris ES for 2 h. TNF- mRNA was normalized to RPLP0
mRNA, and results were displayed as fold change relative to
no treatment. Data illustrate that flagellin was the only TLR
ligand shown to significantly promote TNF- mRNA expres-
sion (6.41  1.7, P  0.05) (Fig. 1A). When IEC were treated
with varying concentrations of flagellin for 2 h, a dose-depen-
dent increase in TNF- mRNA was observed; 0.1 g/ml and 1
g/ml of flagellin significantly promoted TNF- transcription
(6.4  1.6, P  0.03; 8.7  1.8, P  0.01, respectively)
compared with no-treatment control (Fig. 1B). Treatment with
the lowest concentration of flagellin (0.01 g/ml) showed a
nonsignificant increase in TNF- mRNA expression in IEC
(4.0  1.1, P  0.06), providing further support that the
response is dose dependent. SOCS3 mRNA was not signifi-
cantly changed following flagellin treatment compared with
no-treatment control (Fig. 1C).
SOCS3 enhances TLR5-induced TNF- mRNA. Flagellin-
induced TNF- mRNA was measured in SOCS3hi and
compared with control SOCS3norm IEC. As previously ob-
served, TNF- was enhanced in a dose-dependent manner in
SOCS3norm cells (0.01 g/ml: 15.1  5.1, P  0.04; 0.1
g/ml: 21.3  4.3, P  0.01 and 1 g/ml: 31.9  9.9, P 
0.03) compared with no-treatment control (Fig. 2). Surpris-
ingly, flagellin-induced TNF- was enhanced in IEC overex-
pressing SOCS3. Treatment of SOCS3hi with the lowest con-
centration of flagellin (0.01 g/ml) resulted in a 3.8-fold
increase in TNF- mRNA compared with SOCS3norm. Fold
increases of 3.2 and 3.7 were observed in SOCS3hi vs.
SOCS3norm after treatment with 0.1 and 1 g/ml of flagellin,
respectively (P  0.05). However, at 2 h SOCS-mediated
increases in TNF were not detectable in the supernatant
(ELISA data, not shown).
SOCS3 overexpression does not limit flagellin-induced
pSTAT3 or NF-B. To assess whether the impact of SOCS3 on
TNF- was due to differential phosphorylation of STAT3
and/or dissociation of NF-B p65, these transcription factors
were assessed by Western blot (Fig. 3A) in SOCS3norm and
SOCS3hi treated with varying concentrations of LPS and
flagellin for 2 h. As expected, LPS (10 g/ml) induced an
increase in NF-B p65 (1.6  0.07, P  0.04) in SOCS3norm
vs. no-treatment control and SOCS3 overexpression inhibited
LPS-induced p65 (Fig. 3B). Flagellin treatment had no signif-
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Fig. 4. TNFR2 was rapidly downregulated fol-
lowing flagellin treatment. Protein expression
levels returned to baseline by 12 h posttreat-
ment. A: representative photomicrographs of
TNFR2 following flagellin treatment. Immuno-
cytochemistry of IEC, untreated and following
1, 2, 4, 6, or 12 h flagellin treatment (0.1 g/ml).
Green, TNFR2; red, propidium iodide. B: West-
ern blot, confirming TNFR2 immunochemistry
staining and depicting TNFR1 expression fol-
lowing varying time points of flagellin treatment.
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conclude, SOCS3 did not appear to mediate its effects on
flagellin-induced TNF- through differential activation of
pSTAT3 or NF-B.
TLR5 ligation induces transient downregulation of TNFR2.
We performed immunocytochemistry and Western blots to
assess how TLR5 stimulation impacted on IEC TNFR2 protein
expression. TNFR2 expression appeared reduced within 1 h at
the cell surface receptor level and was regained to baseline by
6 h after flagellin treatment (Fig. 4A). SOCS3 overexpression
may delay TNFR2 return to baseline levels, but expression
appeared equivalent to that of control cells 12 h following
treatment. Flagellin did not appear to impact of TNFR1 ex-
pression (Fig. 4B).
SOCS3 limits TLR5- and TLR3-induced increases in TNFR2
transcription. To establish whether SOCS3 inhibits microbial-
induced as well as cytokine-induced TNFR2, mRNA levels
were assessed in response to various TLR ligands; SOCS3
overexpressing IEC (SOCS3hi) and control (SOCS3norm) IEC
were treated with flagellin, Poly(I:C), or LPS for 2 h (Fig. 5).
Most concentrations of flagellin (0.1 and 1 g/ml) and
Poly(I:C) (0.1 g/ml) were shown to significantly enhance
TNFR2 mRNA vs. no-treatment control, by 3.0  0.6, 2.9 
0.3, and 2.9  0.6-fold, respectively (Fig. 5), presumably
accounting for the replenishment of protein expression ob-
served in Fig. 4. However, upregulation of TNFR2 mRNA was
not observed in SOCS3hi IEC in response to either TLR5 or
TLR3 ligation, indicating that SOCS3 inhibits microbial-in-
duced TNFR2 at the transcription level.
SOCS3 limits microbial-induced wound healing. A Caco-2
model of epithelial wound repair was used to determine how
microbial products impact on would healing. LPS and ES
treatment promoted wound healing above that of no-treatment
controls, 21  3.4 and 16  3.7%, respectively (Fig. 6),
whereas flagellin did not promote wound healing (71 vs. 69%
in no-treatment control). SOCS3 overexpression inhibited the
wound healing effect of both LPS and ES.
DISCUSSION
We have shown that SOCS3 promotes TLR5-induced in-
creases in TNF-, an important pathological cytokine in IBD.
TNF- disrupts intestinal epithelial barrier function (29) and
emerging evidence suggests that flagellin is a major driver of
TNF- in pathological inflammation (5). Furthermore, SOCS3
limits microbial-induced transcription of TNFR2, providing
further mechanistic support for its role in regulating homeo-
stasis as well as a tumor suppressor role in the intestine (21). It
is well established that microbial products drive epithelial
repair (20), and accumulating evidence suggest that dysregu-
lated signaling, linked to increased TNF- (29), may impair
epithelial replenishment and repair. Indeed, the observation
that flagellin does not promote wound healing, unlike alterna-





























Fig. 5. SOCS3 limits flagellin (TLR5)- and Poly(I:C) (TLR3)-induced TNFR2
expression. Bar chart indicates relative TNFR2 mRNA following 2-h TLR
ligand treatment of SOCS3norm and SOCS3hi (n  4) relative to No Tx. *P 




































Fig. 6. A: Representative photomicrographs of
TLR-induced epithelial wound repair in
SOCS3norm and SOCS3hi IEC. Wounds mea-
sured at 48 h following injury. B: flagellin
does not promote epithelial wound repair
compared with other microbial products (n 
3). Bar chart indicates percentage wound
healed at 48 h vs. 0 h. *P  0.05 vs. No Tx.
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quence of increased TLR5-driven TNF-, with increased
SOCS3, observed in chronic intestinal inflammation (15, 24),
exacerbating pathological TNF- secretion. Mechanistically,
the limiting effect of SOCS3 on TNFR2 expression could
account for the observed TLR5-induced increases in TNF-.
TNF- regulates the expression of its TNFR2 receptor (4, 13),
presumably to limit excessive signaling, but because SOCS3
limits TNFR2 upregulation in response to flagellin, delaying
the negative feedback loop, IEC may transcribe more TNF- to
compensate, resulting in the chronic inflammation characteris-
tic of IBD. It remains to be determined whether SOCS3 can
drive the increases in TNF- independent of downregulating
TNFR2, or indeed whether increased TNF- transcription is
maintained, but it is likely that these two mechanisms are
interrelated. Alternatively, SOCS3 may promote posttranscrip-
tional degradation of TNF-, through either proteasome (10) or
autophagy (14) mechanisms, and the subsequent cellular re-
sponse is to drive more TNF- transcription to compensate for
the lack of autocrine feedback.
Our findings are in accordance with studies demonstrating
that SOCS3 limits inflammatory cytokine-induced TNFR2 in
colonic IEC (9). The human TNFR2 promoter contains 2
consensus STAT binding sites (22), which may account for the
ability of SOCS3 to limit TNFR2 transcription. However, the
impact of flagellin on TNFR2 is unlikely to be due to inflam-
matory cytokines in our system, since at 2 h posttreatment the
increased TNF- has little time to impact in an autocrine
manner and our lack of detectable TNF- in the supernatant
supports this assumption. Therefore we initially hypothesized
that SOCS3 is likely to directly impact on flagellin-induced
transcription factor binding; however, SOCS3 does not appear
to be limiting NF-B or STAT3 activation in response to TLR5
ligation. In our system flagellin treatment did not result in
increased p65, but SOCS3 did limit p65 following LPS treat-
ment. Flagellin itself does not significantly change SOCS3
mRNA expression, at least at the 2-h time point studied,
supporting the finding that pSTAT3 is not involved in TLR5
signaling of IEC. It remains to be determined whether SOCS3
mediates its impact on TNF- transcription through other
transcription factors. Our results also illustrate the varied
complexity of microbial signaling at the IEC interface. For
example, SOCS3 does appear to limit LPS-induced p65 (Fig.
3B) and flagellin does not appear to impact on TNFR1 expres-
sion (Fig. 4B).
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